363.30p+1.60 (+0.44%)08 Nov 2024, 17:03
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Haleon PLC Fundamentals

Company NameHaleon PLCLast Updated2024-11-08
IndustryDrug Manufacturers - Specialty & GenericSectorHealthcare
Shares in Issue9.103 bnMarket Cap£33.07 bn
PE Ratio33.61Dividend per Share£0.04
Dividend Yield1.56Dividend Cover2.69
EPS£0.11EPS Growth (%)0.05
PEG1.65DPS Growth (%)0
Debt Ratio0.2652Debt Equity Ratio0.4462
Asset Equity Ratio1.9989Cash Equity Ratio0.0318
Quick Ratio0.4742Current Ratio0.84
Price To Book Value1.9790ROCE0

Haleon PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total
Interim2024-08-152024-09-19GBP0.0200
Prelim2024-03-142024-05-16GBP0.0420
Interim2023-08-242023-10-05GBP0.0180
Prelim2023-03-162023-04-27GBP0.0240

Haleon PLC Company Financials

Assets202320222021
Tangible Assets£1.90 bn£1.90 bn£1.66 bn
Intangible Assets£26.86 bn£28.44 bn£27.20 bn
Investments000
Total Fixed Assets£29.24 bn£30.76 bn£29.20 bn
Stocks£1.41 bn£1.35 bn£951.00 m
Debtors£1.86 bn£1.88 bn£3.71 bn
Cash & Equivalents£994.00 m£606.00 m£347.00 m
Other Assets000
Total Assets£34.05 bn£34.81 bn£34.45 bn
Liabilities202320222021
Creditors within 1 year£4.64 bn£4.37 bn£4.24 bn
Creditors after 1 year£12.69 bn£13.99 bn£3.73 bn
Other Liabilities000
Total Liabilities£17.33 bn£18.36 bn£7.97 bn
Net assets£16.73 bn£16.46 bn£26.48 bn
Equity202320222021
Called up share capital£92.00 m£92.00 m£1.00 m
Share Premium000
Profit / Loss£1.63 bn£1.62 bn£1.64 bn
Other Equity£16.61 bn£16.33 bn£26.36 bn
Preference & Minorities£123.00 m£126.00 m£125.00 m
Total Capital Employed£16.73 bn£16.46 bn£26.48 bn
Ratios202320222021
Debt Ratio£0.35£0.38£0.00
Debt-to-Equity£0.53£0.61£0.00
Assets / Equity1.99891.99891.9989
Cash / Equity0.03180.03180.0318
EPS£0.12£0.11£0.15
Cash Flow202320222021
Cash from operating activities£2.10 bn£2.06 bn£1.36 bn
Cashflow before financing£532.00 m£8.97 bn£120.00 m
Increase in Cash£398.00 m£190.00 m£87.00 m
Income202320222021
Turnover£11.30 bn£10.86 bn£9.54 bn
Cost of sales£4.55 bn£4.28 bn£3.60 bn
Gross Profit£6.75 bn£6.58 bn£5.95 bn
Operating Profit£2.00 bn00
Pre-Tax profit£1.63 bn£1.62 bn£1.64 bn

Haleon PLC Company Background

SectorHealthcare
ActivitiesHaleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of salesfrom global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Latest Interim Date8 Jul 2024
Latest Fiscal Year End Date29 Feb 2024

Haleon PLC Directors

AppointedNamePosition
2023-12-19Mr. Manvinder Singh BangaNon-Executive Director,Senior Independent Non-Executive Director
2024-09-27Mr. Brian James McNamaraExecutive Director,Chief Executive Officer
2024-11-01Ms. Dawn Allen
2024-09-27Mr. Tobias HestlerExecutive Director,Chief Financial Officer

Haleon PLC Contact Details

Company NameHaleon PLC
Address980 Great West Road, Brentford, TW8 9GS
Telephone+44 2080475000
Websitehttps://www.haleon.com

Haleon PLC Advisors